Commercial Designation:Human CD4-positive T cells
Catalog Number:LV-CD4+T001
Specifications:1/5million cells per vial
Strain:Southeast Asian populations
Number of Donors:N>10
Lead Time: 1 week
Storage Conditions:Strict liquid nitrogen storage with continuous temperature monitoring, as repeated temperature fluctuations during cryocontainer handling may compromise cell viability post-thawing.
Transport Conditions:Liquid Nitrogen Transportation
Shelf Life:10 years
Quality Control (QC) Parameters :Thawing recovery data (viability; viable cell count; contamination detection)、Cell FACS Analysis (Anti-CD4 Antibody and Other Markers).
Transport Mode
Liquid Nitrogen Transportation
1、Adsorptive Liquid Nitrogen Transportation ,No free liquid nitrogen ,White vapor emission indicates normal operation.
2、Temperature monitoring devices should closely monitor the temperature inside the tank during transportation. If any abnormalities are detected, you can copy the PDF and Excel data from the temperature recorder. (One end of the temperature monitoring device can be unplugged to reveal a USB connector. Simply insert it into a computer to copy the data. If you encounter any difficulties, you can contact the sales staff and technical support for assistance.)
3、Alloy Combination Lock Designed to ensure no third-party access to the LN₂ tank or cell samples during transportation from dispatch to receipt, thereby safeguarding cell integrity.
4、GPS Tracker Enables real-time tracking of cell transportation routes to prevent loss.
5、Liquid Nitrogen Tank, temperature monitoring device, alloy combination lock, and GPS tracker are returnable components. Please store them properly and avoid damage; failure to comply will result in blacklisting.
Reference Citation
blush.
Scope of Application
The research applications of human CD4⁺ T cells can be summarized as the following core directions:
1. Tumor Immunotherapy Mechanism Research
Dual roles in immunosuppression and promotion: Specific subsets such as Tr1 cells inhibit anti-tumor immune responses by killing antigen-presenting classical dendritic cells (cDC1)³, while Th1 cells indirectly induce inflammatory cell death in immune-evading tumors by triggering monocytes to release nitric oxide.
Direct antitumor functions: CD4⁺ T cells can inhibit tumor cell cycle (G1/S phase arrest) by secreting TNF-α, or achieve remote killing of tumors through CAR-T-mediated IFN-γ secretion, with efficacy depending on tumor sensitivity to IFN-γ.
2. Novel Immunotherapy Development
Multispecific antibody therapy: For example, the HER2/CD3×CD28 trispecific antibody activates CD4⁺ T cells to directly inhibit tumor growth and enhance the activity of CD8⁺ T cells.
CAR-T cell optimization: In certain tumor models (such as B-cell leukemia), CD4⁺ CAR-T cells exhibit superior remote killing efficacy via IFN-γ compared to conventional CD8⁺ CAR-T cells.
3. Immune Regulation and Tolerance Mechanisms
Research on Regulatory T Cells (Treg/Tr1): Tr1 cells mediate immunosuppression via interleukin-10 (IL-10) and granzyme B secretion, thereby modulating therapeutic efficacy of cancer vaccines or immune checkpoint inhibitors.
Autoimmune disease models: CD4⁺ Treg cells regulate immune homeostasis in models such as multiple sclerosis (EAE), where they suppress excessive immune responses.
4. Neurological Disorders and Infection Immunity
Neurodegenerative Diseases: CD4+ T cells mitigate β-amyloid deposition through the CXCR6-PD-1 signaling axis, thereby delaying the progression of Alzheimer's disease.
Anti-infective Immunity: Th1 cells activate macrophages through IFN-γ secretion, promoting the clearance of intracellular pathogens such as Mycobacterium tuberculosis.
5. Interorgan Interactions and Metabolic Regulation
Entero-hepatic axis research: CD4⁺ T cells regulate the effects of gut microbiota metabolites (such as LPS) on liver inflammation.
Metabolic diseases: Involvement in the regulation of adipose tissue inflammation in obesity or diabetes models.
Conclusion
The research applications of human CD4⁺ T cells span fields including tumor immunity, autoimmune diseases, neurodegenerative disorders, and metabolic regulation. Their functional heterogeneity (e.g., Th1, Treg, and Tr1 subsets) provides critical mechanistic insights for developing targeted therapies.
由于我司产品说明书半年更新一次,以下步骤仅作参考,以公司随货说明书为准
I 试剂与材料
Ø 冻存CD4阳性T细胞(Cat# LV-CD4+T001/2)
Ø 培养基(完全RPMI1640培养基,见下表)
Ø 37℃恒温水浴锅
Ø 生物安全柜
Ø 15ml离心管
Ø 37℃/5% CO2培养箱
Ø 宽口滴管和宽口移液枪头
Ø 移液枪
Ø 75%酒精
II 完全RPMI1640培养基
成分 | 用量 |
不完全RPMI1640溶液 | 500ml |
左旋谷氨酰胺(L-Glu) | 2mM |
2-巯基乙醇(2-ME) | 50μM |
青霉素(Penicillin) | 100U/ml |
链霉素(Streptomycin) | 100μg/ml |
FCS(56℃灭活30min) | 50ml |
特别提醒:复苏培养基中补加300mM葡萄糖,可提升细胞活力及活细胞数。
III 细胞的复苏与铺板
重要提示:解冻时,冻存细胞转移必须使用液氮转移;在整个复苏实验过程中必须全程使用宽口枪头。
1. 完全RPMI1640培养基放入37℃恒温水浴锅中让其充分预热。
2. 将冻存的细胞从冷藏位置迅速转移至37℃恒温水浴锅中。将冻存管尽可能多的浸入37℃水中,作规律的水平摇动,但必须确保冻存管盖子保持在水面以上。
3. 解冻冻存管至刚好完全溶解成液体,约90-120秒。
4. 用75%酒精对冻存管消毒,并将其转移到生物安全
柜中。
5. 小心地将解冻后的细胞吸出,移至15ml离心管,并
用培养基润洗一遍冻存管及吸取细胞的枪头。
6. 一边摇晃离心管,一边加入完全RPMI1640培养基至12ml(注意:前3ml要缓慢逐滴加入并摇晃,后面9ml可加快速度),最后上下颠倒混匀。
7. 20℃,500g,升速7,降速4,离心8min。
8. 弃上清,加入3ml完全RPMI1640培养基重悬细胞,并用台盼蓝染色计数(V细胞悬液:V0.4%台盼蓝=9:1,细胞活率使用血球计数板手工计数,勿用细胞计数仪;细胞总数使用细胞计数仪计数)测定细胞的活力、细胞总数,建议细胞总数检测3次,求取平均值;为节约时间,细胞活率检测1次。
9. 按实验要求的密度进行铺板。
10. 在37℃/ 5% CO2培养箱中培养。
Thawed cells should not be refrozen, as repeated freezing may affect their function and status.
VI Regarding After-Sales Service
Quality Assurance & After-Sales Policy In the event of product quality issues, please: Collect original data Contact our sales representatives or technical support team immediately We will dispatch personnel to address the issue promptly.
After-Sales Validity Period & Submitted Original Data:
Resuscitation issues: Report any abnormalities immediately and provide results of Trypan blue staining or AO/PI staining.
Contamination issues: Report within 96 hours after resuscitation and provide phase-contrast microscope photos.
Purity issues: Report within one month of detection and provide immunofluorescence or flow cytometry results.
VII Contact Number
Company Telephone:0755-28284050
Technical Support:19902901483( Dr. Zhou)